ProQR Therapeutics N.V. (PRQR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in ProQR Therapeutics N.V., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

ProQR Therapeutics N.V. (PRQR) has returned -19.80% so far this year and 21.80% over the past 12 months. Over the last ten years, PRQR has returned -10.62% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Sep 18, 2014, PRQR's average daily return is +0.09%, while the average monthly return is +1.86%. At this rate, your investment would double in approximately 3.1 years.

Historically, 47% of months were positive and 53% were negative. The best month was Dec 2022 with a return of +200.8%, while the worst month was Feb 2022 at -80.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, PRQR closed higher 45% of trading days. The best single day was Oct 16, 2024 with a return of +122.1%, while the worst single day was Feb 11, 2022 at -75.4%.

ProQR Therapeutics N.V. has an annualized alpha of 11.22%, beta of 0.99, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since September 19, 2014.

• This stock participated in 150.74% of S&P 500 Index downside but only 26.09% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PRQR ranks 50 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for ProQR Therapeutics N.V. (PRQR) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the ProQR Therapeutics N.V.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ProQR Therapeutics N.V. was 97.76%, occurring on May 11, 2022. The portfolio has not yet recovered.

The current ProQR Therapeutics N.V. drawdown is 93.52%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of ProQR Therapeutics N.V. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how ProQR Therapeutics N.V. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.